How would you treat a newly diagnosed hormone sensitive high risk prostate cancer with one small lung metastasis and no other evidence of metastatic disease per PSMA PET?

Per the NCCN guidelines and clinical trials, the patient does not fit the criteria for low metastatic burden, and therefore the benefit of radiation to the prostate is questionable. (Per NCCN: "Conventional imaging defined number of bony metastases without visceral involvement may be preferred to define candidacy for treatment of the primary tumor".) Would you treat the prostate? Would you treat the lung met? Systemic therapy alone?

3 Answers

Mednet Member

Radiation Oncology · Hôtel Dieu de Lévis - CISSS Chaudière-Appalaches

Answered on

I think there is no solid answer to this. De-novo visceral metastases are very rare in mHSPC, and lung-only oligometastases on PSMA-PET are even more rare. Since lung metastases is expected to be visible on CT, this is undeniably a high-volume disease based on the CHAARTED criteria.

Patients with vi...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Radiation Oncology

Answered on

My preferred management strategy would be related to the likelihood I thought the lung lesion was (1) a prostate cancer metastasis, (2) a primary lung cancer (which can be PSMA+), or (3) a false positive from another process. Lung cancers can be PSMA-avid, and having a lung metastasis at diagnosis w...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Radiation Oncology · UC San Diego

Answered on · Updated on

Given the clarifications provided (lung met is biopsy-proven prostate cancer and visible on CT), systemic therapy is clearly the priority. Drs. @Dr. First Last and @Dr. First Last have provided nice summaries of the evidence. I assume neuroendocrine was ruled out. Also, this is a great situation for...

Join for free or sign in to see the full answer